亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Direct Contact Blood Brain Barrier Triculture

總結
Researchers at Purdue University have developed a model that represents a more restrictive, accurate model of the BBB. This model is a direct contact, triculture model containing astrocytes, pericytes, and the brain microvessel endothelial cells (BMEC) configured in a physiologically similar manner to an in vivo BBB. This method allows for direct contact between the pericytes and the astrocytes and measures the transendothelial electrical resistance (TEER) as an indirect measure of cell tightness. Researchers monitor the TEER until they determine a window in which a triculture would be of utility for permeability studies. This model will offer superior selectivity for screening neuroactive or neurotoxicant agents in vitro and help in the rational selection of candidates for advancement into further clinical studies based on its physiological similarity to the in vivo BBB cellular configuration. This model may also be adopted to select compounds that have a lower potential of eliciting a neurotoxicant effect.
技術優勢
More accurate model representing the BBB Allows materials to permeate through it Allows for direct contact between the astrocytes and pericytes
技術應用
Medical/Health Pharmaceuticals Research & Development Drug discovery
詳細技術說明
Gregory KnippKnipp LabPurdue Industrial and Physical Pharmacy
*Abstract

*Background
Neurological disorders have been steadily increasing over the last several decades. While drug discovery and development efforts to mitigate these diseases have concurrently increased to meet the change in prevalence, clinical translation into marketed products have been hindered. One of the main difficulties in creating this translation is the lack of a model that can predict the ability of new chemical entities to permeate through the brain blood barrier (BBB). Current models suffer from leakiness of the in vitro cellular tight junctions and that leakiness leads researchers to overestimate the amount of drug permeation.
*IP Issue Date
None
*IP Type
Provisional
*Stage of Development
Prototype testing validated
*Web Links
Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipGregory KnippKnipp LabPurdue Industrial and Physical Pharmacy
國家
United States
申請號碼
None
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備